Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial ...
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results